Daniel P. Petrylak, MD

Articles

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Petrylak on Future Research in Prostate Cancer

October 22nd 2020

Daniel P. Petrylak, MD, discusses future research in prostate cancer.

Dr. Petrylak on the Utility of Tissue Versus Liquid Biopsy in Prostate Cancer

October 7th 2020

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations

September 28th 2020

Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.

Dr. Petrylak on the Role of PSA Screening in Prostate Cancer

September 28th 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

Dr. Petrylak on the Results of the EV-103 Trial in Bladder Cancer

May 1st 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Dr. Petrylak on Available Treatment Options in Metastatic Bladder Cancer

March 13th 2020

Daniel P. Petrylak, MD, discusses available treatment options in metastatic bladder cancer.

Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

June 4th 2019

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Petrylak on the KEYNOTE-045 Trial for Urothelial Carcinoma

June 9th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancer, discusses the KEYNOTE-045 trial investigating pembrolizumab (Keytruda) versus physician’s choice of chemotherapy for patients with urothelial carcinoma.

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Dr. Petrylak on Trial of Atezolizumab in Urothelial Carcinoma

February 24th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

February 3rd 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer

January 31st 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Dr. Petrylak on Sequencing of Targeted Agents in Bladder Cancer

January 20th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.

Dr. Petrylak on Novel Immunotherapy Research in Bladder Cancer

January 4th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Dr. Petrylak on Immunotherapy in Bladder Cancer

March 28th 2016

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Petrylak on Atezolizumab in Bladder Cancer

December 15th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

Dr. Petrylak on the Future Immunotherapy in Bladder Cancer

May 27th 2015

Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.